Katmai is a clinical-stage biopharmaceutical company founded by a team of leading brain cancer researchers, drug developers and clinicians. We design and develop drugs targeting lethal cancers originating in the brain.

Our proprietary discovery platform enables best-in-class small molecule drugs designed to be highly brain penetrant and selectively target oncogenic driver alterations unique to primary brain tumors.

Katmai is generating expanded opportunities for clinical and commercial success through the development of patient-selection biomarkers, rational drug combinations and novel clinical trial designs.